Kinase Inhibitor Crystal Forms Enhance FLT3 Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic drugs for malignant tumors, such as alkylating agents and small molecule kinase inhibitors, suffer from poor efficacy and severe side effects, highlighting the need for more effective FLT3 kinase inhibitors.
Innovation Solution
Development of specific salt crystal forms and free base crystal forms of a compound with defined X-ray powder diffraction characteristic peaks and DSC spectra, including forms like Form T and Form B, and various salt crystal forms with specific X-ray powder diffraction patterns, to enhance drug stability and bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional therapeutic drugs (alkylating agents, antimetabolites, natural products, antibiotics) are used for malignant tumors, then treatment can be provided, but efficacy is poor and side effects are serious
Solution Approach 1:
The patent applies parameter changes by developing novel FLT3 kinase inhibitors with specific molecular structures (formula I and its salts) that target the FLT3 mutation specifically. This changes the chemical and pharmacological parameters of the treatment, moving from traditional non-specific chemotherapeutics to targeted kinase inhibitors, thereby improving efficacy while reducing off-target side effects
Solution Approach 2:
The patent uses FLT3 kinase as an intermediary target between the drug and the cancer cells. By inhibiting FLT3, which is overexpressed or mutated in AML cells, the drug indirectly affects cancer cell survival and proliferation while sparing normal cells that do not rely on FLT3 signaling, thus improving the therapeutic index
2Reliability
If new FLT3 kinase inhibitors are developed to improve efficacy, then treatment effectiveness increases, but drug stability and bioavailability must be optimized
Solution Approach 1:
The patent optimizes drug stability by developing specific crystal forms (Forms A-S) of the FLT3 inhibitor and its salts. By controlling the crystalline structure and physical state of the compound, the patent improves pharmacokinetic properties including stability, solubility, and bioavailability, which are critical for maintaining effective drug levels in the body
Solution Approach 2:
The patent creates composite pharmaceutical formulations by combining the FLT3 inhibitor with specific counterions to form stable salt crystals. These composite crystal structures enhance the chemical and physical stability of the active ingredient while maintaining its biological activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These crystal forms provide improved stability and potentially increased efficacy as FLT3 kinase inhibitors, addressing the limitations of existing drugs by offering a more targeted and effective treatment for AML.
Implementation Method 1
the free base crystal form Form T has the following X-ray powder diffraction characteristic peaks: 20.644°±0.2°, 17.233°±0.2°, 23.479°±0.2°, 15.867°±0.2°, 20.091°±0.2°
Implementation Method 2
X-ray powder diffraction characteristic peaks
Implementation Method 3
the DSC spectrum of the free base crystal form Form T has three endothermic peaks at 90-95° C., 115-1200° C., and 220-225° C.
Data Source
AI summary
A salt crystal form and a free base crystal form of a kinase inhibitor are provided. Specifically, the kinase inhibitor can be a salt crystal form formed by a compound as shown in formula I and different acids, and a free base crystal form thereof.